Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients

A One-Year Trial of Lamivudine for Chronic Hepatitis B

Ching‐Lung Lai, Rong‐Nan Chien, Nancy W.Y. Leung et al. · New England Journal of Medicine · 1998 · 1.8K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B

Ting‐Tsung Chang, Robert G. Gish, Robert de Man et al. · New England Journal of Medicine · 2006 · 1.4K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +10

Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B

Ching‐Lung Lai, Daniel Shouval, Anna S. Lok et al. · New England Journal of Medicine · 2006 · 1.2K citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +11

Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine

Daniel J. Tenney, Steven M. LeVine, R.E. Rose et al. · Antimicrobial Agents and Chemotherapy · 2004 · 538 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

Kazuaki Chayama, Yoshiyuki Suzuki, Masahiro Kobayashi et al. · Hepatology · 1998 · 375 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +17